Celularity Total Assets from 2010 to 2024

CELUW Stock

USD 0.02 0.0004 1.79%

Celularity Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 136.7 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-03-31

Previous Quarter

143.9 M

Current Value

135.5 M

Quarterly Volatility

126.6 M

Covid

Check Celularity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celularity's main balance sheet or income statement drivers, such as Depreciation And Amortization of 20.6 M, Interest Expense of 2.5 M or Selling General Administrative of 48.1 M, as well as many indicators such as Price To Sales Ratio of 1.84, Dividend Yield of 0.0 or PTB Ratio of 1.13. Celularity financial statements analysis is a perfect complement when working with Celularity Valuation or Volatility modules.

Check out the analysis of Celularity Correlation against competitors.

For more information on how to buy Celularity Stock please use our How to Invest in Celularity guide.

Latest Celularity's Total Assets Growth Pattern

Below is the plot of the Total Assets of Celularity over the last few years. Total assets refers to the total amount of Celularity assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Celularity books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Celularity's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celularity's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 143.89 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Celularity Total Assets Regression Statistics

	Arithmetic Mean	121,330,734
	Geometric Mean	3,305,524
	Coefficient Of Variation	143.05
	Mean Deviation	145,387,533
	Median	174,457
	Standard Deviation	173,561,439
	Sample Variance	30123.6T
	Range	430.8M
	R-Value	0.68
	Mean Square Error	17585T
	R-Squared	0.46
	Significance	0.01
	Slope	26,262,722
	Total Sum of Squares	421730T

Celularity Total Assets History

	2024	136.7 M
	2023	143.9 M
	2022	401.1 M
	2021	414.1 M
	2020	431 M
	2019	291.6 M

Other Fundumenentals of Celularity

Intangibles To Total Assets

Celularity Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Accounts Payable	Net Receivables	Good Will	Capital Surpluse	Intangible Assets	Current Deferred Revenue	Short Term Investments	Deferred Long Term Liab	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Short Long Term Debt
Total Assets		-0.08	0.22	-0.68	0.74	0.83	0.27	-0.7	0.41	0.56	-0.09	0.79	-0.58	-0.55	-0.04	-0.04	0.58	0.49	-0.32	0.28	0.04
Total Stockholder Equity	-0.08		0.64	0.08	-0.73	-0.53	0.42	0.13	0.07	-0.11	-0.08	-0.17	0.08	-0.32	-0.08	-0.08	0.34	0.31	-0.26	0.24	0.07
Net Debt	0.22	0.64		-0.5	-0.28	0.02	0.25	-0.48	0.48	0.56	-0.63	0.35	-0.55	-0.67	-0.58	-0.58	0.7	0.73	-0.84	0.86	0.55
Retained Earnings	-0.68	0.08	-0.5		-0.52	-0.78	0.19	1.0	-0.87	-0.94	0.72	-0.94	0.98	0.9	0.64	0.64	-0.89	-0.9	0.83	-0.79	-0.6
Total Liab	0.74	-0.73	-0.28	-0.52		0.93	-0.09	-0.57	0.24	0.46	-0.01	0.66	-0.45	-0.16	0.02	0.02	0.17	0.13	-0.05	0.03	-0.02
Total Current Assets	0.83	-0.53	0.02	-0.78	0.93		-0.15	-0.81	0.47	0.68	-0.26	0.85	-0.72	-0.49	-0.24	-0.24	0.5	0.45	-0.38	0.35	0.24
Common Stock	0.27	0.42	0.25	0.19	-0.09	-0.15		0.19	-0.15	-0.17	0.11	-0.18	0.18	0.16	0.1	0.1	-0.16	-0.16	0.14	-0.13	-0.09
Net Tangible Assets	-0.7	0.13	-0.48	1.0	-0.57	-0.81	0.19		-0.85	-0.95	0.71	-0.95	0.98	0.87	0.63	0.63	-0.86	-0.87	0.81	-0.78	-0.59
Accounts Payable	0.41	0.07	0.48	-0.87	0.24	0.47	-0.15	-0.85		0.89	-0.81	0.81	-0.88	-0.86	-0.63	-0.63	0.79	0.89	-0.78	0.72	0.54
Net Receivables	0.56	-0.11	0.56	-0.94	0.46	0.68	-0.17	-0.95	0.89		-0.78	0.91	-0.95	-0.83	-0.62	-0.62	0.8	0.88	-0.87	0.84	0.55
Good Will	-0.09	-0.08	-0.63	0.72	-0.01	-0.26	0.11	0.71	-0.81	-0.78		-0.5	0.83	0.68	0.94	0.94	-0.62	-0.74	0.87	-0.86	-0.89
Capital Surpluse	0.79	-0.17	0.35	-0.94	0.66	0.85	-0.18	-0.95	0.81	0.91	-0.5		-0.88	-0.82	-0.36	-0.36	0.81	0.82	-0.68	0.63	0.3
Intangible Assets	-0.58	0.08	-0.55	0.98	-0.45	-0.72	0.18	0.98	-0.88	-0.95	0.83	-0.88		0.87	0.75	0.75	-0.85	-0.89	0.88	-0.85	-0.71
Current Deferred Revenue	-0.55	-0.32	-0.67	0.9	-0.16	-0.49	0.16	0.87	-0.86	-0.83	0.68	-0.82	0.87		0.58	0.58	-0.99	-0.98	0.86	-0.81	-0.54
Short Term Investments	-0.04	-0.08	-0.58	0.64	0.02	-0.24	0.1	0.63	-0.63	-0.62	0.94	-0.36	0.75	0.58		1.0	-0.56	-0.61	0.79	-0.8	-0.99
Deferred Long Term Liab	-0.04	-0.08	-0.58	0.64	0.02	-0.24	0.1	0.63	-0.63	-0.62	0.94	-0.36	0.75	0.58	1.0		-0.56	-0.61	0.79	-0.8	-0.99
Net Invested Capital	0.58	0.34	0.7	-0.89	0.17	0.5	-0.16	-0.86	0.79	0.8	-0.62	0.81	-0.85	-0.99	-0.56	-0.56		0.97	-0.87	0.83	0.52
Capital Stock	0.49	0.31	0.73	-0.9	0.13	0.45	-0.16	-0.87	0.89	0.88	-0.74	0.82	-0.89	-0.98	-0.61	-0.61	0.97		-0.92	0.88	0.55
Net Working Capital	-0.32	-0.26	-0.84	0.83	-0.05	-0.38	0.14	0.81	-0.78	-0.87	0.87	-0.68	0.88	0.86	0.79	0.79	-0.87	-0.92		-1.0	-0.74
Short Term Debt	0.28	0.24	0.86	-0.79	0.03	0.35	-0.13	-0.78	0.72	0.84	-0.86	0.63	-0.85	-0.81	-0.8	-0.8	0.83	0.88	-1.0		0.76
Short Long Term Debt	0.04	0.07	0.55	-0.6	-0.02	0.24	-0.09	-0.59	0.54	0.55	-0.89	0.3	-0.71	-0.54	-0.99	-0.99	0.52	0.55	-0.74	0.76

Click cells to compare fundamentals

About Celularity Financial Statements

Celularity investors use historical fundamental indicators, such as Celularity's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celularity. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	143.9 M	136.7 M
Intangibles To Total Assets	0.13	0.12

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Celularity Stock Analysis

When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC